Riverwater Companions, an funding administration firm, launched its “Small Cap Technique” Q3 2025 investor letter. A duplicate of the letter might be downloaded right here. The Small Cap Core Technique reported stable outcomes for the quarter however didn’t preserve tempo with the sharp rally, thus lagging the benchmark. The market’s choice for lower-quality corporations endured within the quarter and contributed considerably to the benchmark’s outperformance. However, the technique stays centered on higher-quality corporations with enduring fundamentals, constant income, and a clear path to profitability. The agency strongly believes that the technique is well-positioned within the difficult quarter. As well as, you may verify the fund’s prime 5 holdings to find out its greatest picks for 2025.
In its third-quarter 2025 investor letter, Riverwater Companions Small Cap Technique highlighted shares comparable to Haemonetics Company (NYSE:HAE). Headquartered in Boston, Massachusetts, Haemonetics Company (NYSE:HAE) is a medical know-how firm. The one-month return of Haemonetics Company (NYSE:HAE) was 8.06%, and its shares misplaced 2.03% of their worth during the last 52 weeks. On December 15, 2025, Haemonetics Company (NYSE:HAE) inventory closed at $80.40 per share, with a market capitalization of $3.873 billion.
Riverwater Companions Small Cap Technique acknowledged the next concerning Haemonetics Company (NYSE:HAE) in its third quarter 2025 investor letter:
“Haemonetics Company (NYSE:HAE) detracted because the blood administration and hospital provide firm skilled challenges associated to softer-than-expected demand in sure product strains. Whereas these near-term headwinds pressured the inventory, we consider Haemonetics’ important position in hospital blood administration, coupled with new product launches and operational enhancements, help a restoration in efficiency. We exited the place in the course of the quarter to redeploy capital into alternatives with clearer near-term catalysts.”
Haemonetics Company (NYSE:HAE) will not be on our record of 30 Most Common Shares Amongst Hedge Funds. As per our database, 36 hedge fund portfolios held Haemonetics Company (NYSE:HAE) on the finish of the third quarter, which was 29 within the earlier quarter. Within the second quarter of fiscal 2026, Haemonetics Company (NYSE:HAE) reported income of $327 million, marking a 5% reported income decline. Whereas we acknowledge the potential of Haemonetics Company (NYSE:HAE) as an funding, we consider sure AI shares provide larger upside potential and carry much less draw back danger. In case you’re on the lookout for a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring pattern, see our free report on the greatest short-term AI inventory.
